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The use of teriparatide in the management of fracture 
disorders is poorly documented. This study aims to show 
that teriparatide administration may improve the healing 
process in patients with nonunions after open fixation of 
traumatic fractures of the lower limb. 
 
Methods 
Four patients received Teriparatide for management of 
non-unions after open fixation of traumatic fractures of 
the lower limb. 
 
Results 
Teriparatide administration resulted in adequate bone 
callus over the site of nonunion in all the patients, and 
clinical and radiographic evidence of sound union. 
 
Conclusions 
The efficacy of teriparatide in delayed or non unions is 
still unclear. It may induce an angiogenetic response 
which counteracts the features responsible for 
development of non-union. 
 
Level of Evidence: Level IV, therapeutic case series. 
 
Keywords: Fractures; non-union; teriparatide; surgery; 
internal fixation 
Background 
Approximately 5–10% of bone fractures do not heal 
promptly, and require further treatment
1
. Advanced 
therapies for fracture healing are increasingly emerging, 
but it is crucial to assess their clinical effects
2
. By 
stimulating osteoblasts and reducing osteoblast apoptosis, 
intermittent administration of human parathyroid hormone 
(PTH) increases callus formation, improves mechanical 
strength
3
,and results in increased osteoblast life span
4
. 
PTH may increase cancellous bone formation by 
stimulating osteoblasts
5
, with unclear effects on the 
periosteal surface, and decreased risks for vertebral and 
nonvertebral fractures after a median treatment of 19 
months
6
. Human PTH stimulates osteo-progenitor cells to 
proliferate early, differentiate, and produce bone matrix 
proteins, mostly after 1–2 weeks of therapy
7
. In rats, 
human PTH enhances fracture healing, increases 
mechanical and histological properties
3
, and promotes the 
integration of orthopedic implants into the bone
8
, 
improving bone ingrowth and pullout strength
9
. In 
management of osteoporosis, compared to anti-resorptive 
drugs, Teriparatide, recombinant human PTH(1–34), acts 
as bone anabolic agent
10
 on spinal bone mass
11
, restores 
microarchitecture and trabecular connectivity, enhances 
cortical thickness
12
,and improves bone strength, mostly in 
bones rich of cancellous bone
6
. Administered once daily 
through subcutaneous self-injection, it results in a rapid 
and greater increase in vertebral bone mineral density, 
decreases risk of vertebral and non-vertebral fractures in 
postmenopausal women and men with osteoporosis, and 
provides encouraging pre-clinical results in fracture 
healing
13
. Although relatively few data have been 
published on the administration of Teriparatide for 
management of fracture and related complication in 
humans, and no definitive conclusions around its 
effectiveness may be drawn, a once daily subcutaneous 
injection could enhance fracture-healing in humans
14,15
. 
We report on four patients who received Teriparatide for 
management of nonunions after open fixation of traumatic 




A 36-year-old male healthy swimmer, nonsmoking 
sustained a Gustilo III 3B fracture
16
 of the right femur, 
33A3.1 according to the AO classification system, in a 
road accident (Fig 1). He underwent open reduction and 
mono axial external fixation supplemented by Kirschner 
wires (Fig 1). At four weeks, after the soft tissues had 
healed, an external fixator was applied. Imaging two 
months after surgery showed poor bone apposition in the 
medial and posterior aspects of the site of fracture (Fig 2). 
Four months after the initial injury, the distal external 
fixation pins had loosened and there was delay in healing. 
The patient underwent open reduction, fixation and 
stabilization of the fracture with a mono axial fixator 
supplemented with Allomatrix (Wright Medical 
Technology, Inc, Arlington, Tenn)
17,18
. Eleven months 
after the trauma, despite signs of nonunion at radiographic 
evaluation, the external fixator was removed, and the 
patient started to walk in a protected brace. Laboratory 
investigations, including serum alkaline phosphatase, 
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PTH, calcium, creatinine, and 25 (OH) vitamin D were 
normal, excluding any metabolic disorder. After 15 
months from the original trauma, the patient underwent 
open reduction and internal fixation with a condylar plate, 
application of platelet rich plasma and implantation of 
bone allograft. At 20 months, given the poor bone 
integration of the graft and the absence of bone callus, the 
patient started treatment with subctunaneous injection of 
teriparatide (1 injection of 20 μg daily), calcium and 
vitamin D. After 9 months of treatment, the 3D CT 
showed complete integration around the plate and the 
bone graft, with adequate formation of bone callus at the 
site of nonunion (Fig 3). The serum levels of alkaline 
phosphatase, increased during the 9 months of therapy 
with teriparatide, normalised within 3 months of 
interruption of teriparatide administration. At follow up 3 
and 5 years from the last operation, the nonunion was 
healed and the patient was satisfied in terms of daily and 
sport activity. Clinically, a 3.5 cm discrepancy was well 
tolerated and balanced by wearing a shoe with a raise and 
an insole.  
Patient 2  
A 33-year-old healthy non-smoking male underwent 
reduction and external fixation of a post-traumatic (traffic 
accident) Gustilo III 3B fracture of the right tibia and 
fibula, 42A.2 according to the AO classification (Fig 4). 
At 5 months from surgery, given the absence of any signs 
of healing on radiographs, the patient underwent open 
reduction and reamed intramedullary nailing. At 5 months 
from the nailing, the patient continued to report pain, and 
was only able to partially weight bear with two elbow 
crutches. Radiographs showed lack of evident callus, and 
atrophic nonunion.  
The patient started treatment with teriparatide (20 μg 
subcutaneous injection daily), calcium and vitamin D. 
After 4 months of teriparatide administration, radiographs 
showed good integration of the bone around the nail, and 
adequate bone callus over the site of nonunion (Fig 5). 
Ten months later, he returned to his pre-operative 
occupation of insurance salesman and sport activities 
(modern pentathlon).  
Patient 3 
A 28-year-old healthy male nonsmoking truck driver 
sustained a Gustilo III 3B fracture of the left femoral shaft 
(32B.2 by AO classification) and left tibia and fibula 
(43A.3 by AO classification) (Fig 6) after a road accident. 
He underwent reduction and internal fixation using a 
reamed retrograde femoral nail, and external fixation of 
the fracture of the tibia and fibula. At 4 months, 
radiographs showed poor healing, lack of bone callus, and 
atrophic nonunion for both fractures (Fig 7). 
The patient underwent removal of the external fixator of 
the lower leg, and started treatment with teriparatide (20 
μg subcutaneous injection daily), calcium and vitamin D. 
After 3 months of therapy, radiographs showed good 
integration of the bone around the nail, and adequate 
callus over the site of nonunion (Fig 8). Twelve months 
later, he started to work again and had changed sport 
(body building). Flexion of the knee was to 95°, extension 
was full.  
Patient 4 
A 30-year-old healthy, engineer, nonsmoking male 
underwent reduction and external fixation (Hoffmann II 
device) of 43A.3 (by AO classification) Gustilo III 3B 
fracture of the left tibia and fibula. At 4 months, 
radiographs did not show any signs of bone healing (Fig 
9). At that time, the patient underwent removal of the 
external fixator and administration of teriparatide (20 μg 
subcutaneous injection daily), calcium and vitamin D. 
Given the soft tissue impairment, he could only undergo 
hyperbaric therapy and plastic surgical procedures. After 4 
months of therapy, radiographs showed good integration 
of the bone, and adequate bone callus over the site of 
nonunion (Fig 10). Eight months later, he could work and 
swim. Ankle extension was 10°, flexion 20°. 
 
Discussion 
The management of open fractures of the tibia and femur 
is challenging. Advanced age, diabetes, corticosteroid 
treatment, osteoporosis, mechanical and anatomical 
factors predispose to delayed or impaired union of 
fractures
19-24
. Undiagnosed metabolic or endocrine 
disorders of calcium, vitamin D, and parathyroid hormone 
(PTH) impair fracture healing, and are considered 
predisposing factors in up to 85% of nonunions
25
. Internal 
and external fixation can be used for appropriate fracture 
management, with no definite consensus. Autologous 
bone grafting is the current gold standard to aid healing in 
atrophic non-unions
26
, but postoperative pain, infection, 
nerve or vascular injuries, and donor site discomfort may 
complicate this procedure
26
. Allogenic grafts eliminate 
donor morbidity, but may induce immunological 
sensitization
27
. BMPs induce bone regeneration and 
promote repair process
26
, but their exact role with respect 
to type, dose, and carrier, together with their cost-
effectiveness, need further clinical delineation
28
. Bone is a 
dynamic tissue, and PTH regulates bone metabolism and 
calcium homeostasis in both intra and extracellular fluids, 
with direct effects on osteoblasts and  stromal cells, and 
indirect activation of osteoclasts
29
. Since human 
recombinant PTH, teriparatide, reduces the risk of non-
vertebral fragility fractures for 18–30 months after 
discontinuation of treatment, intermittent exposures to 
human PTH (less than 2 h daily) are increasingly used to 
improve and accelerate fracture healing, and enhance bone 
formation in different clinical settings such as the early 
postoperative period after osteosynthesis and joint 
replacement
29
. As teriparatide is expensive, its use at the 
moment should be limited to selected patients presenting 
severe forms of osteoporosis, presence or history of one or 
more fractures, exposed high risk for subsequent fractures, 
or to patients with osteoporosis that have unsatisfactory 
responses to or intolerance of other osteoporosis 
therapies
30
. Given its favorable tolerance and treatment 
compliance, we used teriparatide to treat nonunions after 
surgical management of open fractures of the lower limb, 
with good results in terms of pain relief and imaging 
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outcomes. Primarily used for management of severe post-
menopausal osteoporotic fractures, teriparatide has been 
firstly administered 7 weeks after intramedullary nailing 
in a patient with fractures of the right tibia and fibula
31
. 
The therapy improved clinical and radiographic outcomes 
of the fracture, and the patient returned to run within 3 
months. In a series of 34 patients undergoing fracture 
surgery, teriparatide accelerated healing and allowed early 
return to normal function
32
. A prospective, randomized, 
double blind study of 102 postmenopausal women who 
had undergone conservative management of distal radial 
fractures showed shorter time to healing after 
administration of teriparatide (20 mg)
33
. Although the 
presence of confounding factors does not allow to draw 
consistent conclusions about the role of teriparatide in 
fracture healing, teriparatide may accelerate this process. 
To the best of our knowledge, this is the first case series 
reporting on the use of teriparatide for management of 
nou-union in fractures of the lower limb. Chintamaneni et 
al.
15
 described the first case of sternal fracture nonunion 
responding to treatment with teriparatide, with dramatic 
radiographic healing more than 6 months after the initial 
fracture. Another patient with delayed union of a humeral 
shaft fracture healed after 5 months of therapy with 
teriparatide (rhPTH 1-34), without other interventions
14
. A 
recent prospective randomized controlled study has shown 
that the additional administration of PTH 1-84 (once-daily 
injection of 100 μg) significantly improves functional 
outcomes and fracture healing in women with 
postmenopausal pelvic fractures compared to control 




Side effects of teriparatide include dizziness and leg 
cramps; hypercalcemia is uncommon, and easily managed 
modifying the intake of calcium and vitamin D3
35
. Pre-
clinical studies on rats exposed to high doses of 
teriparatide, from 3 to 58 times the approved dose for 
humans, showed an increased occurrence of 
osteosarcoma
35
, and teriparatide is contraindicated in 
patients with Paget disease of bone, patients who had 
undergone radiotherapy, and children with open 
epiphyses. However, the single case of osteosarcoma 
reported among more than 250,000 patients treated with 
teriparatide in the U.S. and more than 300,000 patients 
treated worldwide, is within the expected background 
incidence of the tumor in the adult population (1 case in 
250,000 patient-years)
35
. In the present investigation, all 
definitive operations were performed by a single surgeon 
and followed at the same department. Limitations of the 
study are the small sample size, short follow-up, and that 
no reliable and sensitive scores were used to assess the 
outcomes. We are aware that all the patients were 
different for type of fracture and surgical procedure 
performed, time from injury to administration of 
teriparatide and length of follow-up, but the 
administration of teriparatide seems to improve bone 
healing in problem fractures. Although the efficacy of 
teriparatide for delayed or non-unions is still unclear, it 
may induce an angiogenetic response which counteracts 
the pathological features responsible for development of 
bone union disorders. Further well-designed studies need 
to assess the efficacy of teriparatide in the setting of 
fracture nonunion. 
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